Imidapril
Clinical data | |
---|---|
Trade names | Tanatril, others |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 42% (imidaprilat) |
Protein binding | 85% (imidapril), 53% (imidaprilat) |
Metabolites | Imidaprilat (active metabolite) |
Elimination half-life | 2 hrs (imidapril), 24 hrs (imidaprilat) |
Excretion | 40% Kidney, 50% bile duct |
Identifiers | |
| |
JSmol) | |
Melting point | 139 to 140 °C (282 to 284 °F) |
| |
| |
(what is this?) (verify) |
Imidapril, sold under the brand name Tanatril among others, is an
It was patented in 1982 and approved for medical use in 1993.[2]
Contraindications
Contraindications are hypersensitivity against ACE inhibitors, especially if it has resulted in
Adverse effects
Common adverse effects are similar to other antihypertensive drugs and include headache,
Interactions
No interaction studies have been conducted except with
Pharmacology
Mechanism of action
Pharmacokinetics
About 70% of the ingested imidapril is absorbed quickly from the gut; this percentage is reduced significantly when taken with a fatty meal. It reaches highest blood plasma concentrations after two hours and has a biological half-life of two hours. The substance is a prodrug and is activated to imidaprilat, which reaches highest plasma concentrations after 7 hours, has an initial half-life of 7 to 9 hours and a terminal half-life of more than 24 hours. The absolute bioavailability of imidaprilat is 42%.[3][4]
About 40% of the drug is excreted via the urine and 50% via the bile and faeces.[3][4]
References
- S2CID 241327668.
- ISBN 978-3-527-60749-5.
- ^ a b c d e Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2019. Tanatril 10 mg-Tabletten.
- ^ ISBN 978-3-7741-9846-3.